Seeking Alpha
 

Enzo Biochem, Inc. (ENZ)

- NYSE
  • Tue, Mar. 31, 5:36 PM
    | Tue, Mar. 31, 5:36 PM | 3 Comments
  • Mon, Mar. 16, 5:41 PM
    | Mon, Mar. 16, 5:41 PM | Comment!
  • Mon, Mar. 16, 12:45 PM
    | Mon, Mar. 16, 12:45 PM | Comment!
  • Aug. 6, 2014, 5:41 PM
    • Top gainers, as of 5:15 p.m.: CST +13.3%. MCP +12.8%. SKYW +8.9%. PRAA +6.5%. EGY +6.3%.
    • Top losers, as of 5:15 p.m.: THOR -26.9%. BWC -12.6%. LIOX -10.5%. ENZ -7.7%. SD -7.1%.
    | Aug. 6, 2014, 5:41 PM | 1 Comment
  • Mar. 7, 2014, 5:37 PM
    • Top gainers, as of 5:15 p.m.: IG +9.3%. MIL +8.4%. EROS +2.9%. YOKU +2.5%. MEET +2.4%.
    • Top losers, as of 5:15 p.m.: NVO -4.2%. OLN -2.9%. ACHN -2.1%. ACO -2.0%. ENZ -1.5%.
    | Mar. 7, 2014, 5:37 PM | Comment!
  • Aug. 5, 2013, 12:22 PM
    • Enzo Biochem (ENZ +8.6%) jumps after a Federal Court Judge upholds the jury verdict issued in November, 2012, which awarded the drug developer $48.6M in damages as a result of patent infringement by Applera Corporation, which is now Life Technologies (LIFE -0.1%).
    • The court ruled initially that LIFE infringed on ENZ's patent covering pioneering technologies relating to compounds used in DNA sequencing systems to read genetic code.
    • The Judge also denied LIFE's request for a finding that Enzo's infringement claims are barred by laches and/or equitable estoppel and its motion for a new trial, as well as ENZ's request for reconsideration seeking additional damages.
    • The ruling opens the way for ENZ to recover prejudgment interest on the damages award, which should exceed $25M in addition to the judgment.
    | Aug. 5, 2013, 12:22 PM | Comment!
  • Nov. 5, 2012, 12:45 PM
    Midday top 10 gainers: NVGN +50%. ICAD +43%. NTE +36%. HMNY +19%. BMRN +30%. OPTT +25%. VRNG +23%. EQU +15%. BEE +13%. BITA +12%.
    Top 10 Losers: EBIX -22%. HGSH -19%. RDN -14%. PCYC -12%. MEAD -15%. VTUS -10%. PKBK -10%. COCO -9%. PGRX -9%. ENZ -9%.
    | Nov. 5, 2012, 12:45 PM | 1 Comment
  • Dec. 13, 2011, 2:03 PM
    Enzo Biochem (ENZ -9.3%) takes a hit after its FQ1 misses across the board. Net losses widened Y/Y, as royalty payments declined and operating expenses jumped 11% due to higher SG&A expenses.
    | Dec. 13, 2011, 2:03 PM | Comment!
Visit Seeking Alpha's
ENZ vs. ETF Alternatives
Company Description
Enzo Biochem Inc is engaged in research, development, manufacturing and marketing of health care products, platforms and services. The Company provides clinical laboratory services.